K. Straley

发表

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.

A. Iafrate, D. Neuberg, K. Yen, 2012, Blood.

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.

Andrei I Holodny, Robert J Young, Ralph Noeske, 2016, Neuro-oncology.

Rapid Transport of Internalized P-Selectin to Late Endosomes and the Tgn

S. Green, K. Straley, 2000, The Journal of cell biology.

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Hua Yang, K. Yen, O. Bernard, 2014 .

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Hua Yang, Fang Wang, Zenon Konteatis, 2017, Cancer discovery.

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

S. Gross, Giovanni Cianchetta, Cheng Fang, 2018, ACS medicinal chemistry letters.

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model

A. Kernytsky, Yaguang Si, S. Gross, 2016, Journal of Inherited Metabolic Disease.

2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels

H. Kohrt, O. Abdel-Wahab, J. Zehnder, 2013, Leukemia & lymphoma.

ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells

Mindy I. Davis, S. Gross, L. Dang, 2013 .

IL-Converting Enzyme/Caspase-1 Inhibitor VX-765 Blocks the Hypersensitive Response to an Inflammatory Stimulus in Monocytes from Familial Cold Autoinflammatory Syndrome Patients

K. Beaumont, P. Larsen, G. Henkel, 2005, The Journal of Immunology.

AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo

A. Melnick, R. Levine, P. Ward, 2014 .

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

P. Opolon, Hua Yang, K. Yen, 2014 .

AP‐3 Adaptor Functions in Targeting P‐Selectin to Secretory Granules in Endothelial Cells

S. Green, J. Sanders, K. Straley, 2001, Traffic.

Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2

A. Futreal, A. Flanagan, M. Eskandarpour, 2011, Nature Genetics.

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

P. Negulescu, P. Grootenhuis, J. Wine, 2011, Proceedings of the National Academy of Sciences.

Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.

James Rader, P. Negulescu, T. Knapp, 2006, American journal of physiology. Lung cellular and molecular physiology.

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Erica Hansen, Francesco G. Salituro, 2013, Science.

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Jeffrey W. Clark, A. Iafrate, D. Dias-Santagata, 2012, The oncologist.

An atypical sorting determinant in the cytoplasmic domain of P-selectin mediates endosomal sorting.

S. Green, K. Straley, S. Aeder, 1998, Molecular biology of the cell.

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

K. Ross, S. Ramaswamy, Kwok-Kin Wong, 2014, Nature.

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.

Wei Liu, Fang Wang, Hua Yang, 2014, Blood.

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

I. Mellinghoff, Cheng Fang, Hua Yang, 2020, ACS medicinal chemistry letters.

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.

S. Gross, Shunqi Yan, J. Saunders, 2012, ACS medicinal chemistry letters.

Mutant IDH is sufficient to initiate enchondromatosis in mice

B. Alman, S. Inoue, T. Mak, 2015, Proceedings of the National Academy of Sciences.

Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.

K. Yen, A. Bardia, A. Fathi, 2014, The oncologist.

Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.

P. Pandolfi, L. Kats, Jiangwen Zhang, 2014, Cell stem cell.

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Jeffrey W. Clark, A. Iafrate, D. Christiani, 2014, Clinical Cancer Research.

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Jeffrey W. Clark, A. Iafrate, D. Christiani, 2014, Clinical Cancer Research.

Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

Iannis Aifantis, Mathieu Lupien, Qinxi Li, 2016, Cancer cell.

Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice

P. Gaulard, S. Inoue, T. Mak, 2016, Proceedings of the National Academy of Sciences.

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

Francine E. Garrett-Bakelman, C. Mason, A. Melnick, 2017, Cancer discovery.

Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1*

Mindy I. Davis, S. Gross, B. Delabarre, 2014, The Journal of Biological Chemistry.

Mutant Isocitrate Dehydrogenase IDH 1 Characterization of a Potent Inhibitor of Biochemical , Cellular , and Biophysical Molecular Bases of Disease

S. Gross, B. Delabarre, L. Dang, 2014 .

Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia

A. Iafrate, D. Neuberg, Hua Yang, 2018, Cancer.

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

D. Margolis, O. Abdel-Wahab, K. Yen, 2012, Blood.

2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels

H. Kohrt, O. Abdel-Wahab, J. Zehnder, 2011 .

mutations and clinical outcome in acute myeloid leukemia Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase

D. Margolis, O. Abdel-Wahab, K. Yen, 2013 .

Title: Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Running Head: 2HG predicts IDH mutations and clinical outcome in AML

Martin, D. Margolis, O. Abdel-Wahab, 2013 .

Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies

I. Mellinghoff, Hua Yang, K. Yen, 2018 .

AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model

S. Choe, Hua Yang, K. Yen, 2013 .

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

Francine E. Garrett-Bakelman, C. Mason, A. Melnick, 2017, Cancer discovery.